Puma Biotechnology, Inc.
PBYI
$7.17
$0.091.27%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 227.18M | 228.37M | 212.00M | 238.06M | 232.71M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 227.18M | 228.37M | 212.00M | 238.06M | 232.71M |
| Cost of Revenue | 58.03M | 58.16M | 48.95M | 65.88M | 64.23M |
| Gross Profit | 169.15M | 170.21M | 163.04M | 172.19M | 168.48M |
| SG&A Expenses | 71.67M | 70.85M | 69.09M | 69.09M | 76.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 197.69M | 191.07M | 178.44M | 192.00M | 195.46M |
| Operating Income | 29.49M | 37.30M | 33.56M | 46.06M | 37.25M |
| Income Before Tax | 29.09M | 35.78M | 30.91M | 42.28M | 31.96M |
| Income Tax Expenses | 4.70M | 4.67M | -6.07M | -6.17M | -6.11M |
| Earnings from Continuing Operations | 24.38 | 31.11 | 36.98 | 48.45 | 38.07 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.38M | 31.11M | 36.98M | 48.45M | 38.07M |
| EBIT | 29.49M | 37.30M | 33.56M | 46.06M | 37.25M |
| EBITDA | 39.41M | 47.44M | 43.28M | 55.94M | 47.27M |
| EPS Basic | 0.49 | 0.62 | 0.75 | 0.99 | 0.77 |
| Normalized Basic EPS | 0.36 | 0.45 | 0.39 | 0.54 | 0.41 |
| EPS Diluted | 0.47 | 0.61 | 0.74 | 0.98 | 0.77 |
| Normalized Diluted EPS | 0.36 | 0.44 | 0.39 | 0.53 | 0.40 |
| Average Basic Shares Outstanding | 201.22M | 199.97M | 198.73M | 197.40M | 195.99M |
| Average Diluted Shares Outstanding | 203.44M | 202.50M | 200.39M | 198.63M | 196.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |